Library
PubMed
research article
Professional

Integrated circuit-microfluidic biosensors for blood-based disease diagnostics-A review.

Source: PubMed, NCBI / U.S. National Library of Medicine

Analytica chimica actaBoilla Sasi Kiran, Lee Gwo-BinPublished 9/15/2026Last synced 6/8/2026Status: syncedPMID: 42242798DOI: 10.1016/j.aca.2026.345549

Integrated circuit (IC)-integrated microfluidic biosensors have revolutionized blood-based diagnostics by merging precise electronic sensing with on-chip sample manipulation. Over the past decade, continuous progress in IC architectures, signal processing, packaging and microfluidic designs has enabled compact, low-power platforms that detect cardiovascular, infectious disease, and cancer biomarkers directly from microliter volumes of blood or plasma. Herein we summarized developments over the decade, highlighting advances in IC front-ends (impedance, capacitive, & electrochemical), time- and frequency-encoded conversion (sigma-delta converters, voltage-controlled oscillators, & capacitance-to-digital/time interfaces), and fluidic strategies spanning capillary-driven, pressure-driven, and hybrid configurations. Limits of detection (LOD), dynamic range, response time, sample volume, and power consumption were compared across an array of devices to evaluate their point-of-care (POC) suitability. We further addressed drift-resilient packaging, on-chip calibration, and machine learning-assisted signal processing as emerging solutions for robust field operations. This review highlights the key design and performance factors that govern the translational potential of IC-integrated microfluidic biosensors for blood diagnostics. It outlines critical challenges in biocompatibility, manufacturability, analytical sensitivity, and standardization, and identifies the co-optimization of ci

Abstract

Integrated circuit (IC)-integrated microfluidic biosensors have revolutionized blood-based diagnostics by merging precise electronic sensing with on-chip sample manipulation. Over the past decade, continuous progress in IC architectures, signal processing, packaging and microfluidic designs has enabled compact, low-power platforms that detect cardiovascular, infectious disease, and cancer biomarkers directly from microliter volumes of blood or plasma. Herein we summarized developments over the decade, highlighting advances in IC front-ends (impedance, capacitive, & electrochemical), time- and frequency-encoded conversion (sigma-delta converters, voltage-controlled oscillators, & capacitance-to-digital/time interfaces), and fluidic strategies spanning capillary-driven, pressure-driven, and hybrid configurations. Limits of detection (LOD), dynamic range, response time, sample volume, and power consumption were compared across an array of devices to evaluate their point-of-care (POC) suitability. We further addressed drift-resilient packaging, on-chip calibration, and machine learning-assisted signal processing as emerging solutions for robust field operations. This review highlights the key design and performance factors that govern the translational potential of IC-integrated microfluidic biosensors for blood diagnostics. It outlines critical challenges in biocompatibility, manufacturability, analytical sensitivity, and standardization, and identifies the co-optimization of circuit design, surface chemistry, and microfluidic operation as essential for translating laboratory prototypes into practical POC diagnostic devices.

Educational only
This information is for general education and is not medical advice. Always talk to a licensed U.S. clinician about your situation, medications, or treatment decisions.